- 145 mg - Fenofibrate BP;
Without a Prescription
Treatment of Hypercholesterolaemia.
Fenofibrate is prescribed as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, TG and Apo B and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate.
Lipid levels should be monitored periodically and consideration should be given to reducing the dosage of Fenofibrate 145 if lipid levels fall significantly below the targeted range.
Treatment with Fenofibrate should be initiated at a dose of 48 mg/day in patients having mild to moderately impaired renal function, and increased only after evaluation of the effects on renal function and lipid levels at this dose.
For adult patients with hypertriglyceridemia, the initial dose is 48 to 145 mg per day. Dosage should be individualized according to patient response, and should be adjusted if necessary following repeat lipid determinations at 4 to 8 week intervals. The maximum dose is 145 mg per day.
For the treatment of adult patients with primary hypercholesterolemia or mixed hyperlipidemia, the initial dose of Fenofibrate 145 is one tablet once daily.
Patients should be placed on an appropriate lipid-lowering diet before receiving Fenofibrate 145 , and should continue this diet during treatment with Fenofibrate 145 . Fenofibrate 145 tablets can be given without regard to meals.
- Hepatic or severe renal dysfunction, including primary biliary cirrhosis and patients with unexplained persistent liver function abnormality;
- Hypersensitivity to Fenofibrate;
- Pre-existing gallbladder disease;
Blister of 10 tablets;